Triple Your Impact This Holiday Season
Triple Your Impact This Holiday Season
Celebrate the holidays with a year-end gift that can go 3x as far to help provide care and support to the millions affected by Alzheimer's disease, and to advance critical research. But please hurry — this 3x Match Challenge ends soon.
Donate NowFirst ALZ-NET Data Readout Marks Milestone in Building Real-World Evidence for Alzheimer’s Treatment
As reported by the Alzheimer’s Association and its partner organizations, ALZ-NET participants show that the demographics of those enrolled are similar to clinical trial populations, and most individuals being treated with anti-amyloid targeting therapies are in an early clinical stage of Alzheimer’s.
Data from a subset of more than 600 patients enrolled and receiving anti-amyloid targeting therapies show safety and effectiveness consistent with results from more tightly controlled clinical trials. Cognitive and functional measures remained stable during the first year of anti-amyloid targeting therapy. Early safety data also suggests that amyloid-related imaging abnormalities (ARIA) rates aligned with expected patterns by therapy type and APOE status, with no ARIA-related deaths reported. Finally, investigators acknowledged that further work is needed to better understand prescribing patterns and continue strengthening the real-world standard of care.
“We are encouraged that initial ALZ-NET data observations reinforce the clinical use of currently approved disease-targeting treatments for early Alzheimer’s, showing safety and effectiveness consistent with clinical trials,” said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer and medical affairs lead, and ALZ-NET co-principal investigator. “This supports our confidence in the use of these treatments across diverse, real-world care settings.
“To continue strengthening this evidence, we need clinicians, health systems and patients to participate. Joining ALZ-NET, and encouraging patients to consent to sharing their data, helps build the real-world evidence needed to advance treatment for all communities,” Carrillo added.
The Association announced today an important expansion of access: researchers and clinicians can now request ALZ-NET datasets to support further research. Once reviewed by the Data Access and Use Committee and approved, teams will receive data that helps clarify how Alzheimer’s treatments are used and how people respond to them in real-world settings. This new capability represents a major step forward; at the same time, ALZ-NET has long been at the forefront of transparency through its publicly available Data Dashboard, offering real-time, high-level information to the field.
About the Alzheimer's Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.
About ALZ-NET
ALZ-NET is the first nationwide, provider-enrolled patient registry dedicated to capturing real-world data on the use of FDA-approved Alzheimer’s therapies. ALZ-NET is transforming how we understand and deliver Alzheimer’s treatment by collecting data from routine care, beyond the controlled setting of clinical trials. The regulatory-grade real-world data provides critical insights into safety, effectiveness, and long-term outcomes, supporting research, informing drug development and guiding earlier, more data-driven clinical decisions. By connecting health care providers, researchers and health systems, ALZ-NET is shaping the future of Alzheimer’s diagnosis, treatment and care.
A directory of clinicians and health systems participating in ALZ-NET is available at alz-net.org/providers.
ALZ-NET is sponsored by the Alzheimer’s Association and operated and managed by the American College of Radiology (ACR). Other partners include the American Society of Neuroradiology (ASNR) and the Department of Biostatistics at Brown University School of Public Health.